Leflunomide: A small step forward in meeting the urgent need for treatment of drug-resistant cytomegalovirus infection

Transplantation

Volumn 90, Issue 4, 2010, Pages 362-363

  Snydman, David R ^a  

^a TUFTS UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BENZIMIDAVIR; CIDOFOVIR; FOSCARNET; FOSCARNET SODIUM; GANCICLOVIR; IMMUNOGLOBULIN; LEFLUNOMIDE;

ANEMIA; ANTIVIRAL RESISTANCE; BONE MARROW TRANSPLANTATION; CLINICAL TRIAL; CROSS RESISTANCE; CYTOMEGALOVIRUS INFECTION; DIARRHEA; DRUG BIOAVAILABILITY; DRUG MEGADOSE; DRUG WITHDRAWAL; ELECTROLYTE DISTURBANCE; GRAFT VERSUS HOST REACTION; HUMAN; LIVER TRANSPLANTATION; MONOTHERAPY; NEPHROTOXICITY; NEUROPATHY; NOTE; ORGAN TRANSPLANTATION; PRACTICE GUIDELINE; PRIORITY JOURNAL; RELAPSE; STEM CELL TRANSPLANTATION; ULCER; URETHRA INJURY; VIREMIA; VIRUS LOAD;

ALGORITHMS; ANTIVIRAL AGENTS; BENZIMIDAZOLES; CYTOMEGALOVIRUS INFECTIONS; DRUG RESISTANCE, VIRAL; GANCICLOVIR; HUMANS; ISOXAZOLES; RIBONUCLEOSIDES; STEM CELL TRANSPLANTATION; TRANSPLANTATION IMMUNOLOGY;

EID: 77955984772     PISSN: 00411337     EISSN: None     Source Type: Journal    
DOI: 10.1097/TP.0b013e3181e8a6c9     Document Type: Note

References (15)

1. Limaye AP, Corey L, Koelle DM, et al. Emergence of ganciclovir-resistant cytomegalovirus disease among solid organ transplant recipients. Lancet 2000; 356: 645.
2. Li F, Kenyon KW, Kirby KA, et al. Incidence and clinical features of ganciclovir-resistant cytomegalovirus diseasein heart transplant recipients. Clin Infect Dis 2007; 45: 439.
3. Avery R. Update in management of ganciclovir-resistant cytomegalo-virus infection. Current Opin Infect Dis 2008; 21: 433.
4. Jacobsen MA. Review of the toxicities of foscarnet. J Acquir Immune Defic Syndr 1992; 5: 11.
5. Mylonakis E, Kallas WM, Fishman JA. Combination antiviral therapy for ganciclovir-resistant cytomegalovirus infection in solid-organ transplantation. Clin Infect Disease 2002; 34: 1337.
6. Humar A, Snydman DR; the AST Infectious Diseases Community of Practice. Cytomegalovirus in solid organ transplantation. Am J Transplant 2009; 9(suppl 4): S78.
7. Kotton CN, Kumar D, Caliendo AM, et al. International consensus guidelinesonthe management ofcytomegalovirusin solid organ transplantation. Transplantation 2010; 89: 779.
8. Chou SW. Cytomegalovirus drug resistance and clinical implications. Transpl Infect Dis 2001; 3(suppl 2): 20.
9. Drew WL, Miner RC, Marousek GI, et al. Maribavir sensitivity of cyto-megalovirus isolates resistant to ganciclovir, cidofovir or foscarnet. J Clin Virol 2006; 37: 124.
10. Avery R, Marty FM, Strasfeld L, et al. Oral maribavir (MBV) for the treatment of resistant or refractory cytomegalovirus (CMV) infections in transplant recipients [Abstract V-1256]. Presented at the 49th Inter-science Conference on Antimicrobial Agents and Chemotherapy, September 2009, San Francisco, CA.
11. Avery RK, Mossad SB, Poggio E, et al. Utility of leflunomide in the treatment of complex CMV syndromes. Transplantation 2010; 90: 419.
12. Waldman WJ, Knight, Blinder L, et al. Inhibition of cytomegalovirus in-vitro and in vivo by the experimental immunosuppressive agent leflunomide. Intervirology 1999; 42: 412.
13. Waldman WJ, Knight DA, Lurain NS, et al. Novel mechanism of inhibition of cytomegalovirus by the experimental immunosuppressive agent leflunomide. Transplantation 1999; 68: 814.
14. Avery RL, Bolwell BJ, Yen-Lieberman B, et al. Use of leflunomide in an allogeneic bone marrow transplant recipient with refractory cytomeg-alovirus infection. Bone Marrow Transplant 2004; 34: 1071.
15. Levi ME, Mandava N, Chan LK, et al. Treatment of multidrug-resistant cytomegalovirus retinitis with systemically administered leflunomide. Transpl Infect Dis 2006; 8: 38.